Sep 6, 2018

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program

Aug 3, 2018

Oncolytics Biotech® Reports 2018 Second Quarter Results

Jul 31, 2018

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

Jun 5, 2018

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

Jun 4, 2018

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting

Jun 1, 2018

Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares

Jun 1, 2018

Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

May 31, 2018

Oncolytics Biotech® Announces Public Offering of Common Shares

May 29, 2018

Oncolytics Biotech® Announces New OTCQX Ticker Symbol

May 25, 2018

Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone